Compare PAHC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAHC | OGN |
|---|---|---|
| Founded | 1946 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2014 | 2020 |
| Metric | PAHC | OGN |
|---|---|---|
| Price | $52.69 | $6.30 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $34.33 | $11.75 |
| AVG Volume (30 Days) | 222.4K | ★ 3.1M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | 0.92% | ★ 1.28% |
| EPS Growth | ★ 1883.33 | N/A |
| EPS | ★ 1.32 | 0.72 |
| Revenue | $833,350,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $17.03 | $0.42 |
| Revenue Next Year | $3.82 | $1.67 |
| P/E Ratio | $39.62 | ★ $8.65 |
| Revenue Growth | ★ 4.12 | N/A |
| 52 Week Low | $16.16 | $6.16 |
| 52 Week High | $56.30 | $15.85 |
| Indicator | PAHC | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.22 | 31.41 |
| Support Level | $37.09 | $6.18 |
| Resistance Level | $56.14 | $7.87 |
| Average True Range (ATR) | 2.28 | 0.19 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 73.36 | 11.98 |
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.